A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

NCT06421298 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Tafolecimab
DRUG: Sintilimab
DRUG: Nab paclitaxel
DRUG: Docetaxel
DRUG: Gemcitabine

Sponsor

Jinghui Wang